Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Q3 2023 Earnings Conference Call November 7, 2023 4:30 PM ET
Company Participants
Christopher James - Vice President, Investor Relations
Joe Ciaffoni - President and CEO
Colleen Tupper - Chief Financial Officer
Scott Dreyer - Chief Commercial Officer
Conference Call Participants
David Amsellem - Piper Sandler
Tim Lugo - William Blair
Serge Belanger - Needham & Company
Les Sulewski - Truist Securities
Operator
Greetings, and welcome to Collegium Pharmaceuticals Third Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions]. Please note that this conference call is being recorded.
I will now turn the call over to Christopher James, Vice President of Investor Relations at Collegium. Thank you. You may begin.
Christopher James
Welcome to Collegium Pharmaceuticals third quarter 2023 earnings conference call. I'm joined today by Joe Ciaffoni, our Chief Executive Officer; Colleen Tupper, our Chief Financial Officer; and Scott Dreyer, our Chief Commercial Officer. Before we begin today's call, we want to remind participants that none of the information presented today is intended to be promotional and then any forward-looking statements made today are made pursuant to the Safe Harbor provision of the Private Securities Litigation Reform Act of 1995.
You are cautioned that such forward-looking statements involve risks and uncertainties including and without limitation, the risks that we may not be able to successfully commercialize our products, that we may incur significant expense and that we may not prevail in current or future litigation pertaining to our business. These risks and other risks of the company are detailed in the company's periodic reports filed with the Securities and Exchange Commission.
Our future results may differ materially from our current expectations discussed today. Our earnings press release and this call will include discussion of certain non-GAAP information. You can find our earnings press release including relevant non-GAAP reconciliations on our corporate website at collegiumpharma.com.
I will now turn the call over to our CEO, Joe Ciaffoni.
Joe Ciaffoni
Thank you, Chris. Good afternoon, and thank you everyone for joining the call. Today we will discuss our progress on delivering a banner year including our financial performance in the third quarter, provide an update on the payer landscape for Xtampza ER and Belbuca and discuss the Nucynta regulatory extension. We'll also share our expectations for the remainder of the year and our outlook for 2024 and beyond. As we build a leading diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, we strive to do good as we do well.